Fig. 2.
Fig. 2. Platelet PLC-β2 mRNA levels in the patient and healthy subjects. / Platelet RNA from the patient (P) and healthy subjects (H) was subjected to RT-PCR in the presence of 32P-dCTP using 2 sets of PLC-β2 primers (A,B) and β-actin primers, under conditions of linearity of amplification, as described in “Patient, materials, and methods.” The products were subjected to gel electrophoresis, transferred to membrane, and analyzed by phosphorimaging. (A) The PLC-β2 primers used were forward: 2864 nt to 2885 nt; reverse: 3328 nt to 3352 nt. P1 and P2 represent patient samples from 2 separate occasions. (B) The PLC-β2 primers used were forward: 3188 nt to 3212 nt, reverse: 4492 nt to 4516 nt, with the latter being in the 3′ untranslated region (see Figure 1).

Platelet PLC-β2 mRNA levels in the patient and healthy subjects.

Platelet RNA from the patient (P) and healthy subjects (H) was subjected to RT-PCR in the presence of 32P-dCTP using 2 sets of PLC-β2 primers (A,B) and β-actin primers, under conditions of linearity of amplification, as described in “Patient, materials, and methods.” The products were subjected to gel electrophoresis, transferred to membrane, and analyzed by phosphorimaging. (A) The PLC-β2 primers used were forward: 2864 nt to 2885 nt; reverse: 3328 nt to 3352 nt. P1 and P2 represent patient samples from 2 separate occasions. (B) The PLC-β2 primers used were forward: 3188 nt to 3212 nt, reverse: 4492 nt to 4516 nt, with the latter being in the 3′ untranslated region (see Figure 1).

Close Modal

or Create an Account

Close Modal
Close Modal